Key facts
- Alcyone Therapeutics’s last known valuation is $166.5M (Nov 2025).
- It has raised $71.8M across 2 recorded rounds; the latest was Early Stage VC ($19.0M) in Nov 2023.
- Notable investors include Cornell University.
- Alcyone Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Jan 2025 ($19.0M sold to 25 investors).
- Status: Acquired/Merged (Operating Subsidiary).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Alcyone Therapeutics
Funding rounds
2 roundsAbout Alcyone Therapeutics
Developer of neural intervention technology designed to treat neurological conditions. The company's technology is based on an engineered combination of micro-fabrication technologies and advanced biomedical engineering, with a core product focus on targeted drug therapy and hydrocephalus, enabling patients with chronic neuropathological conditions to receive improved treatment.
- Sector
- Healthcare
- HQ
- Lowell, MA, United States
- Founded
- 2010
- Employees
- 12
- Website
- alcyonetx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Alcyone Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alcyone Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alcyone Therapeutics in its N-PORT filings yet. We sweep new filings monthly.